On Oct. 22, the U.S. Food and Drug Administration (FDA) approved eltassa (patiromer for oral suspension) to treat hyperkalemia. Read more.
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.